60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
+0.002 (0.85%)
At close: May 17, 2024, 4:00 PM
-0.003 (-1.20%)
After-hours: May 17, 2024, 7:38 PM EDT

Company Description

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.

The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals logo
Country United States
Founded 2010
IPO Date Jul 12, 2023
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Dr. Geoffrey Stuart Dow

Contact Details

1025 Connecticut Avenue Nw, Suite 1000
Washington, District of Columbia 20036
United States
Phone 202-327-5422
Website 60degreespharma.com

Stock Details

Ticker Symbol SXTP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.30
CIK Code 0001946563
CUSIP Number 83006G104
ISIN Number US83006G1040
Employer ID 45-2406880
SIC Code 2834

Key Executives

Name Position
Dr. Geoffrey Stuart Dow Chairman, Chief Executive Officer and President
Tyrone Miller Chief Financial Officer and Treasurer
Dr. Bryan Smith Chief Medical Officer
Kristen Landon Chief Commercial Officer
Jennifer Herz Director

Latest SEC Filings

Date Type Title
May 15, 2024 10-Q Quarterly Report
May 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
May 3, 2024 PRE 14A Other preliminary proxy statements
May 2, 2024 8-K Current Report
Apr 1, 2024 10-K Annual Report
Mar 15, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 20, 2024 8-K Current Report
Feb 2, 2024 8-K Current Report
Jan 31, 2024 424B4 Prospectus